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Background: Percutaneous coronary intervention with placement of a drug-eluting stent in a diabetic patient with
ST-elevation myocardial infarction is a relatively common procedure, and always requires subsequent treatment
with dual antiplatelet therapy. It is sometimes necessary to add oral anticoagulation therapy because of individual
clinical circumstances, which further increases the risk of bleeding.
Case presentation: A 66-year-old hypertensive diabetic man with a history of gastrointestinal bleeding was admitted
with an ST-elevation inferior myocardial infarction that had been evolving over 72 h. Electrocardiography showed ST
segment elevation in the inferior leads and Q waves in the inferior and anterior leads. He reported a similar episode of
chest pain 1 month previously, for which he had not sought medical treatment. Coronary angiography showed
chronic occlusion of the mid-left anterior descending coronary artery, and acute occlusion of the mid-right coronary
artery. He was treated by percutaneous coronary intervention, with placement of a drug-eluting stent in the right
coronary artery. Soon after admission, transthoracic echocardiography showed abnormal left ventricular contractility
and a large left intraventricular thrombus. Three weeks after admission, the patient was discharged on dual antiplatelet
therapy (clopidogrel and aspirin) and oral anticoagulation therapy (acenocoumarol). Four months after discharge,
transthoracic echocardiography showed absence of left ventricular thrombus and resolution of the abnormal
contractility in the area supplied by the revascularized right coronary artery. Given the high risk of bleeding, oral
anticoagulation therapy was stopped. Six months later, transthoracic echocardiography showed recurrent left
ventricular apical thrombus, and an underlying hypercoagulable state was ruled out. Oral anticoagulation therapy was
restarted on an indefinite basis, and dual antiplatelet therapy was continued.
Conclusions: The present case illustrates the need for repeat transthoracic echocardiography following the withdrawal
of oral anticoagulation therapy in patients with ST-elevation myocardial infarction, both to monitor thrombus status
and to assess left ventricular segmental contraction. In patients who require anticoagulation, avoidance of a drug-
eluting stent is strongly preferred and second-generation stents are recommended. The alternative regimen of oral
anticoagulation and clopidogrel may be considered in this scenario. In patients with recurrent intraventricular thrombus
an underlying hypercoagulable state should be ruled out.
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Use of drug-eluting stents in diabetic patients with ST-
elevation myocardial infarction (STEMI) is relatively com-
mon, and subsequent treatment with dual antiplatelet
therapy (DAPT) is invariably required [1]. Concomitant
oral anticoagulation therapy (OAC) is sometimes neces-
sary if the patient has left ventricular (LV) apical
thrombus. Current guidelines on the management of pa-
tients with STEMI emphasize the role of transthoracic
echocardiography (TTE) for assessment of the extent and
degree of wall motion abnormalities and mural thrombi
that would necessitate anticoagulation [2]. However, the
lack of prospective randomized studies precludes the de-
velopment of firm recommendations regarding the use of
triple antithrombotic therapy (combined OAC and DAPT)
in patients at high risk of bleeding. The European Heart
Journal guidelines of 2012 [2] state that patients with mural
thrombi require OAC with vitamin K antagonist therapy
for up to 6 months. According to the 2013 American
College of Cardiology/American Heart Association (ACC/
AHA) guidelines [3], vitamin K antagonist therapy can be
limited to 3 months in patients who have LV thrombus or
are at risk for LV thrombus, such as patients with antero-
apical akinesis or dyskinesis.
Triple antithrombotic therapy increases the risk of
bleeding, and the optimal duration of triple therapy is
unclear, especially in the era of stenting and DAPT. De-
cisions regarding administration of triple therapy after
STEMI should consider stent placement, stent type, and
the relative risks of bleeding and stent thrombosis [4,5].
If LV imaging after 3 months of therapy shows no evi-
dence of thrombus, discontinuation of OAC earlier than
6 months can be considered, especially if there is recov-
ery of apical wall motion [6]. Given the increased risk of
bleeding related to dual and triple antithrombotic ther-
apy, it would be desirable to test simpler drug combina-
tions, and to clarify the optimal duration of treatment
for prevention of further ischemic/thrombotic events.
We present here an elderly diabetic and hypertensive
man who was admitted with acute inferior STEMI. He
reported an episode of severe chest pain 1 month previ-
ously, for which he had not sought medical treatment.
We discuss the unexpected developments and the reso-
lution of his intraventricular thrombus, as well as poten-
tial emerging management strategies for such patients.
Case presentation
A 66 year-old hypertensive man with a 10-year history of
type II diabetes mellitus and a history of gastrointestinal
bleeding was admitted with evolving inferior STEMI dur-
ing 72 hours from the onset of symptoms. Electrocardiog-
raphy (ECG) showed ST segment elevation in the inferior
leads and Q waves in the inferior and anterior leads. The
patient reported a similar episode of chest pain 1 monthpreviously, for which he had not sought medical treatment.
He had signs of low cardiac output during the first 2–3 days
after admission, and was treated with amines. Evolving
ECG changes suggested a subacute inferior myocardial in-
farction as well as an old anterior myocardial infarction.
Coronary angiography on day 7 showed chronic occlusion
of the mid-left anterior descending coronary artery and
acute occlusion of the mid-right coronary artery (RCA),
the latter being identified as responsible for the STEMI.
Myocardial viability was assessed using cardiovascular
magnetic resonance imaging, and percutaneous coronary
intervention (PCI) was performed with placement of a
drug-eluting stent (DES) in the RCA. The stent type was
chosen because of the patient’s diabetes. Early after admis-
sion, TTE showed LV inferior hypokinesis, anterior and ap-
ical akinesis, and a large left intraventricular thrombus
adherent to the septoapical and inferoapical endocardium
(Figure 1, see Additional file 1: Video 1). The LV ejection
fraction was 37%. The patient’s history and test results indi-
cated a probable anterior STEMI 1 month before admis-
sion, and a subacute inferior STEMI. The D-dimer level
was elevated at admission (785 μg/L) and normalized by
the time of discharge (265 μg/L). Three weeks after admis-
sion, he was discharged on DAPT (clopidogrel and aspirin)
and OAC (acenocoumarol). During the following 4 months,
his international normalized ratio (INR) was maintained
between 2.0 and 2.5. Ranitidine was prescribed because of
the triple antithrombotic therapy and the history of gastro-
intestinal bleeding, but proton-pump inhibitors were not
used. At 4 months after discharge, TTE showed absence of
LV thrombus, persistence of LV apical-anterior and anter-
ior akinesis, and resolution of the abnormal inferior wall
contractility in the area supplied by the revascularized
RCA (Figure 2, Additional file 2: Video 2). The LV ejection
fraction was 47%. Considering the high risk of bleeding,
OAC was stopped. Six months after discharge, TTE
showed recurrence of apical thrombus, and the same ab-
normalities of LV segmental contraction observed at
4 months after discharge (Figure 3, Additional file 3: Video
3). At this point the D-dimer level was normal (251 μg/L).
Laboratory tests were performed to rule out hypercoa-
gulable state. His levels of fibrinogen, protein S, protein C,
antithrombin III, Factor V Leiden, lupus antibody, and
homocysteine were all normal. OAC was re-started on an
indefinite basis, and DAPT was continued. One year after
discharge, TTE showed absence of thrombus, and clopi-
dogrel was stopped, but aspirin and OAC were continued.
To date, the patient has not had any episodes of bleeding,
and there has been no evidence of recurrent thrombus on
regular TTE follow-up examinations.
Discussion
Our decision to perform PCI with placement of a DES
at the acute RCA lesion was guided by our patient’s
Figure 1 Early after admission, transthoracic echocardiography showed left ventricular inferior hypokinesis, anterior and apical
akinesis, and a large intraventricular thrombus adherent to the septoapical and infero-apical endocardium.
Figure 2 At 4 months after discharge, transthoracic echocardiography showed absence of left ventricular thrombus, persistence of
apical-anterior and anterior akinesis, and resolution of the abnormal contractility in the area supplied by the revascularized right
coronary artery.
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Figure 3 At 6 months after discharge, transthoracic echocardiography showed recurrence of apical thrombus, and the same
abnormalities of left ventricular segmental contraction observed at 4 months after discharge.
Lacalzada et al. BMC Research Notes 2013, 6:348 Page 4 of 6
http://www.biomedcentral.com/1756-0500/6/348diabetes and the evolving inferior myocardial infarction,
after myocardial viability was confirmed on cardiovascu-
lar magnetic resonance imaging, in accordance with the
current recommendations [1,7]. The reported chest pain
1 month before his admission and his ECG changes sug-
gested an old anterior myocardial infarction. This was
confirmed by changes in LV segmental contraction ob-
served on TTE and invasive coronary angiography. The
patient was discharged on DAPT, to be continued for at
least 6 months, because of the type of stent used. OAC
was also prescribed because of the LV apical thrombus,
which was adjacent to the percutaneously revascularized
ischemic endocardium. This therapeutic combination
clearly increased the risk of bleeding, especially consid-
ering the patient’s age and history of hypertension and
gastrointestinal bleeding [8]. The current consensus is
that patients with mural thrombi should take OAC with
vitamin K antagonist therapy for up to 6 months. How-
ever, this recommendation has not been revised in the
era of stenting and DAPT. The optimal duration of triple
antithrombotic therapy is unknown, and decisions re-
garding therapy should consider the relative risks of
bleeding and stent thrombosis. If LV imaging after
3 months of therapy shows no evidence of thrombus,
discontinuation of OAC earlier than 6 months can be
considered, especially if there is recovery of apical wall
motion [6]. Some authors have concluded that the dur-
ation of vitamin K antagonist therapy can be limited to3 months in patients who have LV thrombus or are at
risk for LV thrombus, such as those with antero-apical
akinesis or dyskinesis, and that the duration of DAPT
required may depend on the type of stent [3]. In our pa-
tient, follow-up TTE showed resolution of both the
thrombus and the abnormal contractility of the apical-
inferior and inferior LV supplied by the revascularized
RCA. Our decision to stop OAC after 4 months was
based on these findings, but DAPT was continued. How-
ever, the subsequent recurrence of thrombus in the same
location suggests that thrombus formation was related
to the non-revascularized apical-anterior and apical-
septal myocardial segments, which were supplied by the
left anterior descending coronary artery and had in-
farcted prior to admission.
There are some previous reports of cases similar to ours,
in which LV thrombus recurred after discontinuation of
OAC, causing cardioembolism years after STEMI [9,10].
When triple antithrombotic therapy is used, an inter-
national normalized ratio (INR) target range of 2.0 to 2.5
is reasonable [3], although prospective data for such treat-
ment are lacking. Our patient had INR values between 2
and 3 in all follow-up tests, so we assume that the recur-
rent apical thrombus was not attributable to a failure of
medical treatment. As he had risk factors for athero-
thrombosis, we did not initially suspect an underlying
hypercoagulable state. As mentioned, D-dimer level was
elevated at admission but had normalized at discharge,
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can indicate a hypercoagulable state, it is a non-specific
marker that may also be elevated in various other condi-
tions, including STEMI. After the recurrence of LV
thrombus despite adequate triple antithrombotic therapy,
laboratory tests for hypercoagulability were performed and
all were normal. In our case we did not use GPIIb-IIIa an-
tagonists, but the additive effects of GPIIb-IIIa antagonists
and prasugrel’s active metabolite on platelet activation, ag-
gregation, and procoagulant activities have been reported
in STEMI patients [11]. Some authors have described
prothrombotic genetic polymorphisms, such as PIA2,
which is a determinant of ischemic stroke in a selected
high-risk hypertensive population [12], or the single-
nucleotide polymorphism of human CaMKIV gene
(CaMK4), which plays a pivotal role in blood pressure
regulation through the control of endothelial nitric oxide
synthase (eNOS) activity. Impairment of CaMK-mediated
activation of eNOS, as in CaMK4 gene deletion, induces
hypertension, [13]. We were unable to test for genetic
polymorphisms related to thrombosis, as described by
other authors [12,13], as such testing is not available in
our setting, and this is one of the principal limitations in
the management of our patient.
When stent placement is required in a patient who
needs subsequent long-term OAC, a bare-metal stent is
generally preferred over a DES [2]. In patients without
diabetes, small vessels, or large lesions requiring OAC
because of atrial fibrillation or LV thrombus, the benefit
of using a DES to prevent restenosis may be outweighed
by the increased risk of bleeding with long-term triple
antithrombotic therapy [14]. A bare-metal stent was not
used in our case because the LV thrombus was detected
after PCI.
The ACC/AHA guidelines [3] recommend 12 months
of DAPT, but some preliminary data indicate that the
rate of stent thrombosis may be very low when DAPT is
discontinued at 6 months or maybe even 3 months after
placement of a second-generation DES, such as an
everolimus- or zotarolimus-eluting stent [15,16]. The
randomized Efficacy of Xience/Promus versus Cypher to
Reduce Late Loss in Stent (EXCELLENT) trial compared
6 months versus 12 months of DAPT, and everolimus-
eluting versus sirolimus-eluting stents. The trial found that
first-generation stents appear to have a higher rate of late
stent thrombosis than second-generation stents, and
second-generation stents are therefore preferred in patients
who need a DES and subsequent triple antithrombotic
therapy [17].
The recent randomized controlled What is the Op-
timal antiplatElet and anticoagulant therapy in pa-
tients with oral anticoagulation and coronary StenTing
(WOEST) trial [18] found that among patients who
underwent PCI with subsequent OAC, treatment withclopidogrel and OAC was associated with a significantly
lower risk of bleeding than treatment with aspirin,
clopidogrel, and OAC. The sample size was small, but
the investigators saw no evidence of increased risk of
thrombotic events by withholding aspirin. This suggests
a possible alternative therapeutic approach for patients
such as ours, using only OAC and clopidogrel. Physi-
cians should be aware that genetic susceptibility to
hypercoagulable states may favor the appearance or per-
sistence of thrombus, related to mechanisms independ-
ent of the traditional cardiovascular risk factors. The
need to investigate genetic polymorphisms related to
thrombosis should be assessed on an individual basis.
Conclusion
The present case illustrates the need for repeat TTE at
least 3 months after the withdrawal of OAC in STEMI
patients, as recommended by the guidelines. It is import-
ant to confirm the resolution of any LV thrombus and
associated wall motion abnormalities. When there is oc-
clusion of two or more coronary arteries supplying the
apical area, it is not easy to determine which occlusion
is related to thrombus formation. In patients undergoing
primary PCI who require subsequent OAC, avoidance of
a DES is strongly preferred. However, the benefits of a
DES over a bare-metal stent may outweigh the risks in
some cases. When a DES is deemed necessary, a second-
generation stent is preferred if the patient requires sub-
sequent triple antithrombotic therapy. An alternative
regimen of OAC and clopidogrel, without aspirin, may
be considered in such cases. In patients with recurrent
intraventricular thrombus unexplained by inadequate
antithrombotic therapy, genetic polymorphisms related
to thrombosis should be investigated.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Additional files
Additional files 1: Video 1. Early after admission, transthoracic
echocardiography showed left ventricular inferior hypokinesis, anterior
and apical akinesis, and a large intraventricular thrombus adhered to the
septoapical and inferoapical endocardium.
Additional files 2: Video 2. At 4 months after discharge, transthoracic
echocardiography showed the absence of left ventricular thrombus, the
persistence of apical-anterior and anterior akinesis, and recovery of
impaired revascularized right coronary artery -dependent segmentary
contractility.
Additional files 3: Video 3. At 6 months after discharge, transthoracic
echocardiography again showed the presence of an apical thrombus, as
well as the same alterations of left ventricular segmentary contractility
observed on transthoracic echocardiography at 4 months after discharge.
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